Ionis Pharmaceuticals, Inc. (IONS)
IONSNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$28.81
-2.19 (-7.06%) today
Regular session, Nov 10, 2:44 PM ET
- Market cap
- $4.79bn
- P/E
- –
- EPS, last 4 quarters
- $-3.33
- Dividend yield
- –
- Day range
- $28.08 to $30.49
- 52-week range
- $27.75 to $86.74
- Average volume
- 3.77m
- Previous close
- $31.00
Analysts
19 coveringBuy18 buy, 1 hold, 0 sell
Targets a year out average $73.22, +154.1% from here
Earnings
next estimate $-1.08Next report
Dec 2025
-7.6%
Mar 2026
+37.1%
Jun 2026
+35.8%
Sep 2026
+45.9%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $203.33m | $246.09m | $267.95m | $242.72m |
| Gross profit | $195.37m | $243.11m | $265.21m | $239.40m |
| Operating income | -$214.46m | -$117.42m | -$102.29m | -$130.70m |
| Net income | -$229.39m | -$92.53m | -$114.65m | -$109.97m |
Last four quarters: revenue $960.09m, margin -56.9%, free cash flow -$616.26m
News
8 latest- Stock Indexes Surge as Buyers Return to Chipmakers and AI StocksBarchart · 23 minutes ago
- Ionis: 3 Key Takeaways for Long-Term InvestorsThe Motley Fool · 19 hours ago
- Stock Indexes Sharply Higher as Tech Stocks Rally and Crude Oil FallsBarchart · 19 hours ago
- Ionis (IONS) Q3 2026 Earnings Call TranscriptThe Motley Fool · 20 hours ago
- Strength in Tech and Weakness in Crude Oil Boost StocksBarchart · 20 hours ago
- Relative Strength Alert For Ionis Pharmaceuticals BNK Invest · 22 hours ago
- What Ionis Pharmaceuticals (IONS) Said on Its Q3 Earnings CallMarketBeat · 1 day ago
- Ionis Pharmaceuticals, Inc. Q3 Loss Declines RTTNews · 1 day ago
The company
For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has marketed medicines and a leading pipeline in neurology, cardiometabolic disease and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- ionis.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.